APLT stock touches 52-week low at $0.3 amid sharp annual decline

Applied Therapeutics Inc (NASDAQ:APLT) stock has plummeted to a 52-week low, trading at $0.3, as the company grapples with a staggering 1-year change of -93.52%. With a market capitalization of just $44.17 million and a beta of 1.89 indicating high volatility, InvestingPro analysis suggests the stock is currently undervalued. This significant drop reflects a tumultuous period for the biopharmaceutical firm, which has faced challenges that have severely impacted investor confidence and market valuation. Despite the bearish sentiment, the company maintains a healthy current ratio of 3.06, indicating strong short-term liquidity. The 52-week low serves as a critical indicator of the current bearish sentiment surrounding the stock, marking a concerning milestone for stakeholders and potential investors who are closely monitoring the company’s performance and future prospects. Discover 15 additional key insights about APLT with an InvestingPro subscription, including comprehensive financial health metrics and expert analysis.

In other recent news, Applied Therapeutics has announced the appointment of Todd F. Baumgartner as its new Chief Regulatory Officer. Dr. Baumgartner brings over 35 years of experience in the pharmaceutical industry, having previously held leadership roles at companies like Ovid Therapeutics (NASDAQ:OVID) and Acorda Therapeutics (OTC:ACORQ). His expertise in regulatory affairs is expected to support the company’s focus on developing treatments for rare diseases, including its lead drug candidate, govorestat. In another development, Applied Therapeutics has received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement. The company’s stock has closed below the $1.00 minimum bid price for 30 consecutive business days, putting its listing at risk. Applied Therapeutics has until August 6, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. The company is currently evaluating its options to address this issue, although no specific course of action has been decided. Investors are advised to keep an eye on these developments as the company navigates these challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.